Protalix BioTherapeutics Management
Management criteria checks 4/4
Protalix BioTherapeutics' CEO is Dror Bashan, appointed in Jun 2019, has a tenure of 6.42 years. total yearly compensation is $1.53M, comprised of 24.5% salary and 75.5% bonuses, including company stock and options. directly owns 3.08% of the company’s shares, worth $4.66M. The average tenure of the management team and the board of directors is 4.8 years and 5.8 years respectively.
Key information
Dror Bashan
Chief executive officer
US$1.5m
Total compensation
| CEO salary percentage | 24.49% |
| CEO tenure | 6.4yrs |
| CEO ownership | 3.1% |
| Management average tenure | 4.8yrs |
| Board average tenure | 5.8yrs |
Recent management updates
Recent updates
Protalix BioTherapeutics aims for $3.20 by year-end amidst strong revenue growth
As of right now the stock as a current yield of about 2.42%, with a return on equity of about 6.79%. So a bit off of my goals of at least 5% and 10%. However over the last 3 years revenue has grown on
PRX-115 Trials And Elfabrio Launch Will Open Future Markets
Successful Phase II trials and Chiesi's involvement with Elfabrio could drive growth through new marketable products and increased market adoption.Analysts Expect Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) To Breakeven Soon
Feb 22
Have Insiders Been Buying Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares This Year?
Jan 14Could The Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Ownership Structure Tell Us Something Useful?
Dec 10CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | US$5m |
| Jun 30 2025 | n/a | n/a | US$6m |
| Mar 31 2025 | n/a | n/a | US$4m |
| Dec 31 2024 | US$2m | US$374k | US$3m |
| Sep 30 2024 | n/a | n/a | -US$10m |
| Jun 30 2024 | n/a | n/a | -US$15m |
| Mar 31 2024 | n/a | n/a | US$7m |
| Dec 31 2023 | US$3m | US$357k | US$8m |
| Sep 30 2023 | n/a | n/a | US$11m |
| Jun 30 2023 | n/a | n/a | US$9m |
| Mar 31 2023 | n/a | n/a | -US$16m |
| Dec 31 2022 | US$1m | US$360k | -US$15m |
| Sep 30 2022 | n/a | n/a | -US$18m |
| Jun 30 2022 | n/a | n/a | -US$18m |
| Mar 31 2022 | n/a | n/a | -US$24m |
| Dec 31 2021 | US$1m | US$374k | -US$28m |
| Sep 30 2021 | n/a | n/a | -US$21m |
| Jun 30 2021 | n/a | n/a | -US$21m |
| Mar 31 2021 | n/a | n/a | -US$14m |
| Dec 31 2020 | US$1m | US$352k | -US$7m |
| Sep 30 2020 | n/a | n/a | -US$7m |
| Jun 30 2020 | n/a | n/a | -US$6m |
| Mar 31 2020 | n/a | n/a | -US$9m |
| Dec 31 2019 | US$566k | US$175k | -US$18m |
Compensation vs Market: Dror's total compensation ($USD1.53M) is about average for companies of similar size in the US market ($USD1.53M).
Compensation vs Earnings: Dror's compensation has been consistent with company performance over the past year.
CEO
Dror Bashan (58 yo)
Mr. Dror Bashan has been President, Chief Executive Officer and Director of Protalix BioTherapeutics, Inc. since June 30, 2019. He has experience in the pharmaceutical industry with roles ranging from busi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.4yrs | US$1.53m | 3.08% $ 4.7m | |
| Senior Vice President of Operations | 7.5yrs | US$639.96k | 0.29% $ 437.9k | |
| Senior VP & CFO | less than a year | no data | no data | |
| Vice President of Human Resources | 3.3yrs | no data | no data |
Experienced Management: PLX's management team is considered experienced (4.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.4yrs | US$1.53m | 3.08% $ 4.7m | |
| Independent Director | 17.3yrs | US$45.00k | 0.0095% $ 14.4k | |
| Independent Director | 11yrs | US$45.00k | 0.39% $ 583.7k | |
| Independent Director | 5.8yrs | US$45.00k | 0.0093% $ 14.1k | |
| Member of Scientific Advisory Board | 9.4yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3.4yrs | US$33.75k | 0.0093% $ 14.1k | |
| Chairman of Scientific Advisory Board | no data | US$55.00k | no data | |
| Independent Chairman | 2.2yrs | US$70.00k | 0.0093% $ 14.1k | |
| Independent Director | 5.8yrs | US$46.35k | 0.0094% $ 14.2k | |
| Director | less than a year | no data | 0.0093% $ 14.1k |
Experienced Board: PLX's board of directors are considered experienced (5.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/19 15:14 |
| End of Day Share Price | 2025/11/19 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Protalix BioTherapeutics, Inc. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ritu Baral | Canaccord Genuity |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Peter Welford | Jefferies LLC |